Amneal Pharmaceuticals (AMRX) Free Cash Flow (2017 - 2026)

Amneal Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$34.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 506.85% year-over-year to -$34.9 million in Q1 2026; TTM through Mar 2026 was $240.8 million, a 4.09% decrease from a year earlier, with the FY2025 full-year figure at $269.9 million, up 11.0% from the prior year.
• Free Cash Flow fell to -$34.9 million in Q1 2026 per AMRX's latest filing, from $108.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $130.0 million in Q1 2023 and bottomed at -$130.6 million in Q2 2022.
• The 5-year median for Free Cash Flow is $69.7 million (2023), against an average of $47.0 million.
• Across the five-year window, Free Cash Flow surged 462.39% in 2023 and sank 506.85% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$34.8 million in 2022, then jumped by 462.39% to $126.0 million in 2023, then fell by 18.29% to $102.9 million in 2024, then rose by 5.46% to $108.5 million in 2025, then tumbled by 132.17% to -$34.9 million in 2026.
• Per Business Quant, the three latest AMRX Free Cash Flow figures stand at -$34.9 million (Q1 2026), $108.5 million (Q4 2025), and $106.2 million (Q3 2025).